In this episode of the EY Health Sciences and Wellness Experience podcast, Derron Stark talks with Olaf Zweig and Famke Krumbmüller.
The speakers talk about the EY report Pharma supply chains of the future and discuss the impact of global events and how a new supply chain model can emerge.
Until recently, the pharma industry has been on the straight path to globalization with integrated supply chains that crossed national borders. A series of geopolitical upheavals though, from the COVID-19 pandemic, to the crisis in Ukraine, caused the industry to re-examine its priorities.
The COVID-19 pandemic and global political tensions highlighted the downsides of a highly integrated supply chain with global dependencies. Politicians started seeking greater guarantees of national and regional supply, rebalancing supply chains to national security and interests.
The discussion then moves to the response of the pharma industry in incorporating regionalization. A hybrid model is emerging that combines globalized thinking with greater self-sufficiency. The key is end-to-end visibility so that companies have a clear line of sight of their supply chain, enabling manufacturing to continue, even in the face of short-term crises, geopolitical tensions, or cyberattacks.
Two positives that emerged from the COVID-19 pandemic were greater collaboration between pharma companies, demonstrated by the vaccine development, and greater dialogue with policy makers. The way forward is the development of a partnership between pharma companies, policy makers, and regulatory bodies to build a new, resilient supply chain model.
Key takeaways:
- Global tensions and crises have put pressure on pharma companies to re-examine their supply chains.
- The emerging model is a hybrid one that combines globalization with regionalization.
- End-to-end visibility is essential, not just with suppliers but with suppliers of suppliers.
- The supply chain of the future will involve public/private partnerships and greater collaboration between stakeholders.
For your convenience, full text transcript of this podcast is also available. Read the transcript.
Presenters
Derron Stark
EY-Parthenon Managing Director, Strategy and Transactions, Ernst & Young LLPOlaf Zweig
EY-Parthenon Partner, Life Sciences, EY-Parthenon GmbHFamke Krumbmüller
EY EMEIA Leader, Geostrategic Business GroupPodcast
Episode 09
Duration 23m 55s
In this series
Series overviewHow the path to a sustainable health system unlocks value
Episode 08
Presenters
EY Global Health Leader
How life sciences companies are measuring their ESG impact
Episode 07
Presenters
Partner, Strategy and Transactions, EY-Parthenon B.V.
How unlocking the power of data can fuel better health outcomes
Episode 06
Presenters
EY Global Health Sciences and Wellness Industry Leader and Life Sciences Industry Leader
Executive Vice President & Chief Information and Technology Officer for McKesson Corporation
How women are shaping the life sciences industry
Episode 05
Presenters
EY Global Health Sciences and Wellness Industry Leader and Life Sciences Industry Leader
SVP, People, BenevolentAI
How data can help redesign the health experience
Episode 04
Presenters
EY Global Health Sciences and Wellness Industry Leader and Life Sciences Industry Leader
Board Director of Benevolent AI and Chair of the Brainomix Board and the Stevenage Bioscience Park
How shorter clinical trial processes prolong the lives of patients
Episode 03
Presenters
Cell and Gene Therapy Global Business Lead, ICON
EY Global Digital, Social and Commercial Innovation Life Sciences Leader
How digital solutions will help close the health equity gap
Episode 02
Presenters
MD, Chief Medical Officer, Microsoft
MD, US Health Consulting Executive Director, Ernst & Young LLP
The age of ‘Health Experience’
Episode 01
Presenters
EY Global Health Sciences and Wellness Industry Leader and Life Sciences Industry Leader